Vaccines Market Top Players- PFIZER INC, GlaxoSmithKline plc., Merck & Co., Inc., Sanofi, Johnson & Johnson Services, Inc, Panacea Biotec Limited

The vaccines market was valued at US$ 39,128.3 million in 2019 and is projected to reach US$ 64,538.4 million by 2027; it is expected to grow at a CAGR of 6.5% from 2020 to 2027.

A vaccine is a biological preparation that provides active acquired immunity against a particular disease. A vaccine consists of an agent that resembles or is a part of the disease-causing microorganism and is often made from weakened or killed forms of the microorganism, its toxins, or one of its surface proteins. The agent triggers the body's immune system to recognize the agent as a threat, destroy it, and to further recognize and destroy any of the microorganisms associated with that agent that it may encounter in the future.
Request Sample Copy Of this Report @ http://bit.ly/3mrMUtF

VACCINES– MARKET SEGMENTATION

By Technology
• Recombinant vaccines
• Conjugate Vaccines
• Live Attenuated Vaccines
• Inactivated Vaccines
• Toxoid Vaccines

By Disease Indication
• DTP (diphtheria, tetanus, and pertussis)
• Influenza
• Hepatitis
• Dengue
• Cytomegalovirus (CMV)
• Respiratory Syncytial Virus (RSV)
• Other Diseases

By Route of Administration
• Oral
• Injectable
• Other

Purchase Copy of this Report @ http://bit.ly/2IWggTc
Rising prevalence of infectious diseasesis expected to boost the market growth over the years
In the current era, there are increasing concerns of spread of infectious diseases with the changing environment. These emerging infectious diseases are a burden on public health but have also an impact on global economies. The new diseases such as HIV, hepatitis, dengue have attracted a huge concern for the government of the respective countries. There is also resurgence of diseases which seemed to be under control such as malaria, cholera and many more. According to the Centers for Disease control and Prevention in 2015, 16.8 million people in the US visited hospitals due to infectious and parasitic diseases. In Africa, chronic viral hepatitis affects around 70 million Africans (60 million with Hepatitis B and 10 million with Hepatitis C). The disease impacts the most important part of the African population i.e. youths and earning African population which are causing tremendous rise in financial debts incurred for the treatment of advanced liver diseases and emotional distress.In developed countries, the cases of infectious diseases has decreased in the past decade, but there has been a rise of re-emerging diseases worldwide, such as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), measles, avian and pandemic influenza, chikungunya virus, Ebola virus disease (EVD) and Zika virus disease, which has attracted a renewed focus on infectious diseases around the developed countries.Thus the growing global prevalence of infectious diseases are expected to encourage the leading market players for the development of new and effective drugs and vaccines.

Contact:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.

This release was published on openPR.